Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2010

Open Access 01-10-2010 | Proceedings

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone

Authors: Edgardo Rivera, Henry Gomez

Published in: Breast Cancer Research | Special Issue 2/2010

Login to get access

Abstract

Resistance to chemotherapy is a major obstacle to the effective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the effect is not long lasting. Consequently, there is a significant need for new agents with low susceptibility to common drug resistance mechanisms in order to improve response rates and potentially extend survival. Approximately 30% of the women diagnosed with early-stage disease in turn progress to metastatic breast cancer, for which therapeutic options are limited. Current recommendations for first-line chemotherapy include anthracycline-based regimens and taxanes (paclitaxel and docetaxel). They typically give response rates of 30 to 70% but the responses are often not durable, with a time to progression of 6 to 10 months. Patients with progression or resistance may be administered capecitabine, gemcitabine, vinorelbine, albumin-bound paclitaxel, or ixabepilone, while other drugs are being evaluated. Response rates in this setting tend to be low (20 to 30%); the median duration of responses is <6 months and the results do not always translate into improved long-term outcomes. The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting.
Literature
1.
O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005, 10 (Suppl 3): 20-29. 10.1634/theoncologist.10-90003-20.PubMedCrossRef
2.
3.
Cortes J, Baselga J: Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007, 12: 271-280. 10.1634/theoncologist.12-3-271.PubMedCrossRef
4.
Gralow JR: Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005, 89 (Suppl 1): S9-S15. 10.1007/s10549-005-0143-z.PubMedCrossRef
5.
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005, 23: 7794-7803. 10.1200/JCO.2005.04.937.PubMedCrossRef
6.
Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S: Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994, 12: 1639-1647.PubMed
7.
Giaccone G, Pinedo HM: Drug resistance. Oncologist. 1996, 1: 82-87.PubMed
8.
Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001, 92: 1759-1768. 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A.PubMedCrossRef
9.
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ: Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxanecontaining therapy. Ann Oncol. 2003, 14: 1227-1233. 10.1093/annonc/mdg346.PubMedCrossRef
10.
Wist EA, Sommer HH, Ostenbad B, Risberg T, Bremnes Y, Mjaaland I: Oral capecitabine in anthracycline- and taxane-pretreated advanced/ metastatic breast cancer. Acta Oncol. 2004, 43: 186-189. 10.1080/02841860310023165.PubMedCrossRef
11.
Lee JJ, Swain SM: Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol. 2005, 32: S22-S26. 10.1053/j.seminoncol.2005.09.013.PubMedCrossRef
12.
Seidman AD: Monotherapy options in the management of metastatic breast cancer. Semin Oncol. 2003, 30: 6-10.PubMedCrossRef
13.
Shigeoka Y, Itoh K, Igarishi T, Ishizawa K, Saeki T, Fujii H, Minami H, Imoto S, Sasaki Y: Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol. 2001, 31: 370-374. 10.1093/jjco/hye082.PubMedCrossRef
14.
Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994, 5: 423-426.PubMed
15.
Slammon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRef
16.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Olivia C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355: 2733-2743. 10.1056/NEJMoa064320.PubMedCrossRef
17.
Mariani G, Gianni L: Adjuvant trastuzumab in early breast cancer. Ann Oncol. 2006, 17 (Suppl 10): x54-x58. 10.1093/annonc/mdl237.PubMedCrossRef
18.
19.
Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5: 275-84. 10.1038/nrc1590.PubMedCrossRef
20.
21.
Yagüe E, Arance A, Kubitza L, O'Hare M, Jat P, Oglivie CM, Hart IR, Higgins CF, Raguz S: Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 2007, 67: 1130-1137. 10.1158/0008-5472.CAN-06-2574.PubMedCrossRef
22.
Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001, 7: 1429-1437.PubMed
23.
Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000, 1470: M79-M91.PubMed
24.
Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 2005, 205: 275-292. 10.1002/path.1706.PubMedCrossRef
25.
Leonessa F, Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003, 10: 43-73. 10.1677/erc.0.0100043.PubMedCrossRef
26.
Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a metaanalysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997, 89: 917-931. 10.1093/jnci/89.13.917.PubMedCrossRef
27.
Larkin A, O-Driscoll L, Kennedt S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M: Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer. 2004, 112: 286-294. 10.1002/ijc.20369.PubMedCrossRef
28.
Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C, Brunet-Lecomte P, Fargeot P: MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res. 1999, 19: 3575-3581.PubMed
29.
Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Pohl G: Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat. 2003, 81: 149-157. 10.1023/A:1025751631115.PubMedCrossRef
30.
Tsukamoto F, Shiba E, Taguchi T, Sugimoto T, Watanabe T, Kim SJ, Tanji Y, Kimoto Y, Izukura M, Takai SI: Immunohistochemical detection of P-glycoprotein in breast cancer and its significance as a prognostic factor. Breast Cancer. 1997, 4: 259-263. 10.1007/BF02966518.PubMedCrossRef
31.
Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wierner EA, Stoter G, Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003, 9: 827-836.PubMed
32.
Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M: Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res. 2000, 20: 4373-4377.PubMed
33.
Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000, 92: 1295-1302. 10.1093/jnci/92.16.1295.PubMedCrossRef
34.
Filipits M, Pohl G, Rudas M, Dietze O, Las X, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R: Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2005, 23: 1161-1168. 10.1200/JCO.2005.03.033.PubMedCrossRef
35.
Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003, 22: 7340-7358. 10.1038/sj.onc.1206938.PubMedCrossRef
36.
Bunting KD: ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 2002, 20: 11-20. 10.1002/stem.200011.PubMedCrossRef
37.
Staud F, Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol. 2005, 37: 720-725. 10.1016/j.biocel.2004.11.004.PubMedCrossRef
38.
Zhou J, Giannakakou P: Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005, 5: 65-71. 10.2174/1568011053352569.PubMedCrossRef
39.
Drukman S, Kavallaris M: Microtubule alterations and resistance to tubulin-binding agents [review]. Int J Oncol. 2002, 21: 621-628.PubMed
40.
Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M: Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001, 61: 5803-5809.PubMed
41.
Wang Y, Cabral F: Paclitaxel resistance in cells with reduced β-tubulin. Biochim Biophys Acta. 2005, 1744: 245-255. 10.1016/j.bbamcr.2004.12.003.PubMedCrossRef
42.
Kamath K, Wilson L, Cabral F, Jordan MA: βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005, 280: 12902-12907. 10.1074/jbc.M414477200.PubMedCrossRef
43.
Giannakakou P, Gussio R, Nogales E, Downing KH, Zaherevitz D, Bollbuck B, Poy G, Sackett D, Nicolaue KC, Fojo T: A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000, 97: 2904-2909. 10.1073/pnas.040546297.PubMedPubMedCentralCrossRef
44.
He L, Yang CP, Horwitz SB: Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther. 2001, 1: 3-10.PubMed
45.
Verills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, Haber M, Kavallaris M: Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol. 2003, 10: 597-607. 10.1016/S1074-5521(03)00141-8.CrossRef
46.
Zhangg CC, Yang JM, White E, Murphy M, Levine A, Hait WN: The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene. 1998, 16: 1617-1624. 10.1038/sj.onc.1201658.CrossRef
47.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Bucholz TA, Kuerer H, Green M, Arun B, Hotobagyi GN, Symmans WF, Pusztai L: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005, 102: 8315-8320. 10.1073/pnas.0408974102.PubMedPubMedCentralCrossRef
48.
Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI: Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull Cancer. 2004, 91: E81-E112. 10.1038/sj.bjc.6601995.PubMed
49.
Berrieman HK, Lind MJ, Cawkwell L: Do β-tubulin mutations have a role in resistance to chemotherapy?. Lancet Oncol. 2004, 5: 158-164. 10.1016/S1470-2045(04)01411-1.PubMedCrossRef
50.
Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, Schittulli F, Lousso V: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005, 16 (Suppl 4): iv14-iv19. 10.1093/annonc/mdi902.PubMed
51.
Tomassi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Larusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A: Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins. Int J Cancer. 2007, 120: 2078-2085. 10.1002/ijc.22557.CrossRef
52.
Mozetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G: Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005, 11: 298-305.
53.
Valkov NI, Sullivan DM: Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol. 1997, 34: 48-62.PubMed
54.
Lage H, Dietel M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol. 1999, 125: 156-165. 10.1007/s004320050258.PubMedCrossRef
55.
Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D: Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer. 2001, 93: 571-576. 10.1002/ijc.1356.PubMedCrossRef
56.
Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul L, Kaye SB, Brown R: Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol. 2000, 18: 87-93.PubMed
57.
Son BH, Ahn SH, Ko CD, Ka IW, Gong GY, Kim JC: Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004, 10: 20-26. 10.1111/j.1524-4741.2004.09609.x.PubMedCrossRef
58.
Oudin C, Bonnetain F, Boidot R, Végran F, Soubeyrand MS, Arnould L, Riedinger JM, Lizard-Nacol S: Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy. Int J Oncol. 2007, 30: 1145-1151.PubMed
59.
O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N, Duffy MJ: Caspase 3 in breast cancer. Clin Cancer Res. 2003, 9: 738-742.PubMed
60.
Végran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S: Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res. 2006, 12: 5794-5800. 10.1158/1078-0432.CCR-06-0725.PubMedCrossRef
61.
O'Connor PM, Jackman J, Bae I, Myeres TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AR, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57: 4285-4300.PubMed
62.
Aas T, Børresen AL, Geisler S, Smith-Søresnsen B, Jonsen H, Varhaug JE, Akslen LA, Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811.PubMedCrossRef
63.
Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J: Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol. 2005, 16: 743-748. 10.1093/annonc/mdi150.PubMedCrossRef
64.
Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999, 17: 1061-1070.PubMed
65.
Pandolfi PP: Breast cancer – loss of PTEN predicts resistance to treatment. N Engl J Med. 2004, 351: 2337-2338. 10.1056/NEJMcibr043143.PubMedCrossRef
66.
Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, Schofield AC: Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 2004, 6: R601-R607. 10.1186/bcr918.PubMedPubMedCentralCrossRef
67.
Sládek NE, Kollander R, Sreerama L, Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2002, 49: 309-321. 10.1007/s00280-001-0412-4.PubMedCrossRef
68.
DeGregorio MW, Perez EA: Molecular mechanisms of drug resistance. Cecil Textbook of Medicine. Edited by: Bennett JC, Plum F. Philadelphia, PA. 1996, W.B. Saunders Company, 1056-1060.
69.
Bedard PL, Di Leo A, Piccart-Gebhart M: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol. 2010, 7: 22-36. 10.1038/nrclinonc.2009.186.PubMedCrossRef
70.
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka : Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer. 1998, 34: 1274-1281. 10.1016/S0959-8049(98)00058-6.PubMedCrossRef
71.
Blum JL, Jones SE, Buzdar AU: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999, 17: 485-493.PubMed
72.
Bollag DM, McQuenney PA, Zhi J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55: 2325-2333.PubMed
73.
Gerth K, Berforf N, Höfle G, Irschik H, Reichenbach H: Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum(Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo). 1996, 49: 560-563.CrossRef
74.
Nogales E, Wolf SG, Khan IA, Ludeña RF, Downing KH: Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature. 1995, 375: 424-427. 10.1038/375424a0.PubMedCrossRef
75.
Bode CJ, Gupta ML, Reiff EA, Suprenant KA, Georg GI, Himes RH: Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002, 41: 3870-3874. 10.1021/bi0121611.PubMedCrossRef
76.
Nettles JH, Li K, Cornett B, Krahn JM, Snyder JP, Downing KH: The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science. 2004, 305: 866-869. 10.1126/science.1099190.PubMedCrossRef
77.
Kolman A: Activity of epothilones. Curr Opin Investig Drugs. 2005, 6: 616-622.PubMed
78.
Jordan MA, Miller H, Ray A: The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone [abstract LB-280]. Proc Am Assoc Cancer Res. 2006, 47: 73-
79.
Lee FY, Camuso A, Castenada S, Fager K, Flefleh C, Inigo I, Johnson K, Kan D, McGlinchey K, Peterson R, Smykla S, Wen ML, Fairchild C, Kramer R: Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res. 2006, 47: Abstract 503-
80.
Pivot X, Dufresne A, Villanueva C: Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer. 2007, 7: 543-549. 10.3816/CBC.2007.n.009.PubMedCrossRef
81.
Long BH, Wang L, Lorica A, Wang RC, Brattain MG, Casazza AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991, 51: 5275-5283.PubMed
82.
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997, 272: 17118-17125. 10.1074/jbc.272.27.17118.PubMedCrossRef
83.
Wartmann M, Altmann KH: The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002, 2: 123-148. 10.2174/1568011023354489.PubMedCrossRef
84.
Vansteenkiste J, Lara PN, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007, 25: 3448-3455. 10.1200/JCO.2006.09.7097.PubMedCrossRef
85.
Fojo AT, Menefee M, Poruchynsky MS: A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells [abstract 4541]. J Clin Oncol. 2005, 23: 388S-
86.
Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhill SR, Abbruzzese JL: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs. 2006, 24: 515-520. 10.1007/s10637-006-8440-x.PubMedCrossRef
87.
McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002, 8: 2035-2043.PubMed
88.
Thomas E, Taberon J, Fornier M, Conté P, Furnoleau P, Lluch A, Vahdat LT, Bunnell Cam Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Levwohl D, Martin M: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007, 25: 3399-3406. 10.1200/JCO.2006.08.9102.PubMedCrossRef
89.
Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bossserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007, 25: 3407-3414. 10.1200/JCO.2006.09.3849.PubMedCrossRef
90.
Bunnel C, Vahdat L, Schwatzberg L, Gralow J, Klimovsky J, Poulart V, Peck R, Thomas E: Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008, 8: 234-241. 10.3816/CBC.2008.n.026.CrossRef
91.
Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8: 235-244. 10.1016/S1470-2045(07)70074-8.PubMedCrossRef
92.
Thomas E: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007, 25: 5210-5217. 10.1200/JCO.2007.12.6557.PubMedCrossRef
93.
Lerzo GL: Phase III study of ixabepilone plus capecitabine in metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis in HER2+ disease [abstract 151]. ASCO Annual Meeting Proceedings. 2007, San Francisco
94.
Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW: A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010, 119: 663-671. 10.1007/s10549-009-0658-9.PubMedPubMedCentralCrossRef
95.
Picot XB, Lee RK, Tomas ES, Chung H, Fein LE, Chan VF, Jassem J, Hurtado de Mendoza F, Mukhopadhyay P, Roché HH: Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor (ER) status [abstract #221]. ASCO Annual Meeting Proceedings. 2007, San Francisco
96.
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Furnoleau P, Winograd B: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996, 14: 1858-1867.PubMed
97.
Winer EP, Berry DA, Woolf S, Duggan D, Kodnblith A, Harris LN, Michaelson RA, Kirshnew JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol. 2004, 22: 2061-2068. 10.1200/JCO.2004.08.048.PubMedCrossRef
98.
Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005, 23: 5542-5551. 10.1200/JCO.2005.02.027.PubMedCrossRef
99.
Lee JJ, Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006, 24: 1633-1642. 10.1200/JCO.2005.04.0543.PubMedCrossRef
100.
Blum JL, Savin MA, Edelman G: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007, 7: 850-856. 10.3816/CBC.2007.n.049.PubMedCrossRef
101.
Dieras V, Viens P, Veyret C, Romieur G, Awada A, Lidbrink W, Bonnefoi H, Mery-Mignard D, Dalenc F, Roché H: Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): interim analysis of an open phase II label study [abstract 1070]. ASCO Annual Meeting Proceedings. 2008, Chicago
102.
Sartor AO, Oudard S, Ozguroglue M, Hansen S, Machiels JH, Shen L, Gupta S, De Bono JS: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. ASCO Annual Meeting Proceedings. 2010, Chicago
103.
Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer [abstract CRA501]. ASCO Annual Meeting Proceedings. 2009, Orlando
104.
Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract 1019]. ASCO Annual Meeting Proceedings. 2010, Chicago
105.
Reed SD, Li Y, Anstrom KJ, Schulman KA: Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2009, 27: 2185-2191. 10.1200/JCO.2008.19.6352.PubMedCrossRef
Metadata
Title
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Authors
Edgardo Rivera
Henry Gomez
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2573
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits